- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
September 30, 2020Robins Kaplan Named One of BTI’s “Most Feared Firms in Litigation”
-
September 29, 2020Robins Kaplan Announces Diversity and Inclusion Committee Leadership Transition
-
September 22, 2020New York Law Journal Recognizes Hollis Salzman as a Trailblazer
-
October 1-2, 2020Minnesota CLE 2020 Midwest IP Institute
-
October 1, 2020Berkeley Law COVID-19 and the Courts Symposium
-
October 1, 7, and 13, 2020Truth or Fiction? Representations of Wealth Disputes in Television, Literature, and Film—and Implications for Practitioners and Clients
-
Summer 2020Following a Varied Legal Career, Judge Jonathan Kobes Begins on the Eighth Circuit
-
September 22, 2020Herbal Patent Protection
-
August 24, 2020Hot off the Presses: California Further Regulates Out-of-State Adjusters in the Wake of Record-Breaking Catastrophic Losses
The America Invents Act:
Changes in the Patent Laws of Special Interest to the Life Sciences Industry
November 4, 2011
After several years of unsuccessful attempts, Congress recently passed the Leahy-Smith America Invents Act (the ‘‘AIA’’),1 containing the most significant changes to the Patent Act in more than 60 years. President Obama signed the AIA into law on Sept. 16.2 This article presents an overview of the major provisions that are significant for practitioners in the life sciences.3
1 H.R. 1249 (112th Congress).
2 Pub. L. No. 112-29.
3 The authors recognize that there is no monolithic ‘‘life sciences industry’’ that speaks with one voice on all issues, but instead use this term to address views that may be common or shared among individuals and entities advancing or using technologies in the biomedical or biotechnological sciences.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.